SecBot SecBot
PRESS-RELEASE ·Filed Apr 30, 2026

AXSM

Axsome Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Focus on launch metrics (prescriptions, patient starts) and payer coverage for the new indication. The existing commercial presence for MDD may accelerate uptake. Monitor competitor activity in Alzheimer's agitation (e.g., brexpiprazole). Revenue guidance updates in upcoming earnings will be key.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$207.75
T+0 close · Apr 30, 2026 · via day close
Latest settled
+14.74%
T+60 · $238.37
Vs SPY
+11.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $207.75entry
  2. T+1 · 7mo ago −0.59%α −0.81% · $206.53
  3. T+5 · 6mo ago +7.16%α +5.43% · $222.63
  4. T+20 · 6mo ago +12.07%α +7.10% · $232.83
  5. T+60 · 4mo ago +14.74%α +11.63% · $238.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agitation associated with dementia due to Alzheimer's disease, a second indication for the drug. The approval, granted under Priority Review with Breakthrough Therapy designation, addresses a large unmet need affecting up to 76% of the 7+ million Alzheimer's patients in the U.S. This label expansion significantly expands AUVELITY's commercial opportunity beyond its existing major depressive disorder indication.

Key Facts

  • FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026
  • Approval based on Phase 3 ADVANCE-1 and ACCORD-2 studies showing statistically significant improvement in agitation symptoms and longer time to relapse
  • Alzheimer's disease affects >7 million Americans; agitation reported in up to 76% of patients
  • AUVELITY already approved for major depressive disorder (2022) with >300,000 patients exposed and commercial infrastructure in place
  • Patent protection extends to at least 2043

Financial Impact

Approval opens a large new market: up to ~5.3 million Alzheimer's patients with agitation. AUVELITY's existing MDD revenue was $X (not disclosed); this indication could materially accelerate revenue growth.

revenue

Risk Factors

  • Boxed warning for suicidal thoughts and behaviors may limit use in elderly patients
  • Competition from other treatments for Alzheimer's agitation (e.g., brexpiprazole) and off-label antipsychotics
  • Reimbursement and pricing dynamics could slow adoption

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285345

Track record

26 reports on AXSM

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +13.40% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026